Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8273913 | 1.00 | CYP3A4 (0.52) | CYP3A4TSHRCYP2C19SIGMAR1CHRM2 | |
| SCHEMBL522470 | 1.00 | CYP3A4 (0.52) | CYP3A4TSHRCYP2C19SIGMAR1CHRM2 | |
| SCHEMBL522055 | 1.00 | CYP3A4 (0.52) | CYP3A4TSHRCYP2C19SIGMAR1CHRM2 | |
| SCHEMBL6615394 | 0.92 | SIGMAR1 (0.51) | CYP3A4TSHRCYP2C19SIGMAR1CHRM2 | |
| SCHEMBL6615398 | 0.92 | SIGMAR1 (0.51) | CYP3A4TSHRCYP2C19SIGMAR1CHRM2 | |
| SCHEMBL31045650 | 0.84 | SIGMAR1 (0.47) | CYP3A4TSHRCYP2C19SIGMAR1CHRM2 | |
| SCHEMBL17595166 | 0.82 | SIGMAR1 (0.51) | SIGMAR1CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL694189 | 0.81 | CHRM2 (0.62) | CYP2C19CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL16766562 | 0.81 | CHRM2 (0.62) | CYP2C19CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL16766586 | 0.81 | CHRM2 (0.62) | CYP2C19CHRM2CHRM4CHRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528921-B1 | 7-AZONIABICYCLO [2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20160296497-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9320731-B2 | 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof | THERON PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140249195-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8742131-B2 | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof | THERON PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8426611-B2 | 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof | THERON PHARMACEUTICALS INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130059898-A1 | 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120029044-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249195-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRM3, CHRM2, CHRM1 | CYP3A4 403/4885TSHR 227/4885CYP2C19 716/4885 |
| US-20130059898-A1 | 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRM3, CHRM2, CHRM1 | CYP3A4 342/4885TSHR 317/4885CYP2C19 611/4885 |
| US-20160296497-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRM3, CHRM2, CHRM1 | CYP3A4 403/4885TSHR 227/4885CYP2C19 716/4885 |
| US-20120029044-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRM3, CHRM2, CHRM1 | CYP3A4 300/4885TSHR 285/4885CYP2C19 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.